2026 LegislativE AND REGULATORY Priorities

Appropriate Medicare Payment for Diagnostic Radiopharmaceuticals:

Monitor and engage CMS, Congress, and the Administration on Medicare Outpatient Prospective Payment System (OPPS) payment policy, ASP methodology, site-neutral payment proposals, and related executive actions affecting government radiopharmaceutical reimbursement.

Expand patient access to therapeutic radiopharmaceuticals:

Engage NRC and Congressional stakeholders and monitor rulemaking to address regulatory barriers to patient access for therapeutic radiopharmaceuticals.

Regulatory Review, Dispensing, and Administration of Radiopharmaceuticals:

Engage FDA, NIST, NABP, and other stakeholders to improve regulatory oversight, inspection processes, and clinical trial pathways for radiopharmaceuticals.

Good Manufacturing Practices to Produce Positron Emission Tomography Drugs:

Monitor and provide input on FDA updates to PET drug manufacturing standards.

Safe Transportation of Medical and Industrial Radioisotopes:

Evaluate international transportation standard updates and implement CORAR responses as needed. This to include CORAR next steps regarding the approved IAEA revisions to the A1/A2 values for alpha emitters.

Reliable and sustainable supply of medical and industrial isotopes:

Engage Administration trade, security, and nuclear agencies to address tariffs, sanctions, and production policies impacting isotope supply and sustainability.